Skip to main content
Premium Trial:

Request an Annual Quote

Genewiz, KeyTest Collaborate on MDx Development in China

NEW YORK (GenomeWeb News) – Genewiz and KeyTest Diagnostics today announced a collaboration aimed at developing molecular diagnostic tests for the Chinese market.

In addition to developing tests using cutting-edge genomics technologies, the partners said they aim to establish clinical testing standards.

"Partnering with KeyTest Diagnostics will enable Chinese customers to gain access to clinical tests that are critical to disease treatment and their overall health," Amy Liao, president and COO of South Plainfield, NJ-based Genewiz said in a statement. "Together, we will have the ability to develop and introduce more clinical tests in China, thus helping to make a difference in the pursuit of scientific discoveries and better medicines around the globe."

Financial and other terms of the deal were not disclosed.

Genewiz is a contract research organization specializing in genomics services, including DNA sequencing, gene synthesis, and molecular biology. Among its products are OncoGxOne cancer panels for detecting genomic aberrations. The panels can be used for therapeutic target and biomarker discovery, as well as patient stratification for clinical trials, it said.

KeyTest is headquartered in Suzhou, China, and is a third-party medical testing center. Its specialties include laboratory management, molecular diagnostics, clinical immunology, and oncology, among others.